Q4 and is likely to become significantly profitable and cash flow positive in 2025. Read my analysis on ARGX stock here.

Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

It is incredible to see the strong early adoption of VYVGART Hytrulo in CIDP patients ... our sustainable future with our strong balance sheet and transition to profitability in 2025.

The appointment comes at a crucial time for Dianthus, which maintains a strong financial position with more cash than debt on its balance sheet ... Polyneuropathy (CIDP), and Multifocal Motor ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Call Transcript February 18, 2025 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.26, expectations were $1.17 ...

The appointment comes at a crucial time for Dianthus, which maintains a strong financial position with more cash than debt on its balance sheet, as highlighted by ... Chronic Inflammatory ...

The biotech put the message out in a direct-to-consumer TV ad that paints Vyvgart Hytrulo as a drug that can help people with chronic inflammatory demyelinating polyneuropathy (CIDP) live life to ...

Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering.

Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H’25Phase 3 CAPTIVATE trial of ...

“We are excited to have initiated our pivotal Phase 3 CAPTIVATE trial in CIDP, which is on track for an interim responder analysis in 2H’26, along with top-line results from our Phase 2 trial ...